Postgraduate research opportunities Are protease-activated receptors a novel target for the treatment of glioblastoma?
ApplyKey facts
- Opens: Sunday 1 November 2026
- Number of places: 1
- Duration: 36 months
Overview
Gliobastoma (GBM) is one the most aggressive brain tumours for which there are limited treatments and is fatal in almost all patients. Recently, proteinase-activated receptors (PARs1-4), which have been implicated in various inflammation-related diseases [1,2], have been shown to be present in GBM using transcriptomics [3].Eligibility
An upper second-class UK Honours degree, or overseas equivalent, in biomedical engineering or a biology related subject.
If English is not your first language, you must have an IELTS score of at least 6.5 with no component below 5.5.
Project Details
In this project, a variety of in vitro techniques will be performed to determine the consequence of PAR activation and inhibition on signalling pathways, cell survival and proliferation. We will also aim to expand the study to in vivo study using PAR2 activators that we have previously shown to be active in vivo for CNS disorders.
This project aims to investigate the mechanobiology mechanism in the right heart and the role of mechanics on right heart failure in PAH.
Further information
A bench fee of £10,000 per annum is required towards the experimental consumables required for this project.
Funding details
While there is no funding in place for opportunities marked "unfunded", there are lots of different options to help you fund postgraduate research. Visit funding your postgraduate research for links to government grants, research councils funding and more, that could be available.
Supervisors
Dr Natividad Gomez-Roman
Senior Lecturer
Strathclyde Institute of Pharmacy and Biomedical Sciences
Apply
Number of places: 1
To read how we process personal data, applicants can review our 'Privacy Notice for Student Applicants and Potential Applicants' on our Privacy notices' web page.
SIPBS (Pharmacy)
Programme: SIPBS (Pharmacy)